| Prevymis (letermovir) / Merck (MSD) |
NCT05914675: Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCT |
|
|
| Not yet recruiting | 4 | 21 | NA | Letermovir | Institute of Hematology & Blood Diseases Hospital | The Incidence of Peripheral Blood CMV Activation and Confirmed Clinically Significant CMV Infection Within 24 Weeks After Transplantation | 12/24 | 12/24 | | |
NCT05914701: Secondary Prophylaxis of CMV Infection Using Letermovir After HID-HSCT |
|
|
| Not yet recruiting | 4 | 31 | NA | Letermovir for secondary prophylaxis, secondary prophylaxis of CMV reactivation | Institute of Hematology & Blood Diseases Hospital | To Evaluate the Efficacy and Safety of Secondary Prophylaxis of CMV Reactivation | 12/24 | 12/24 | | |
NCT06001320: De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients |
|
|
| Recruiting | 4 | 60 | US | Letermovir 480 mg once daily, Historical/Control | Virginia Commonwealth University, Merck Sharp & Dohme LLC | Kidney Transplant; Complications, CMV | 09/25 | 09/26 | | |
| Active, not recruiting | 4 | 31 | US | Letermovir | Tufts Medical Center, Merck Sharp & Dohme LLC | Cytomegalovirus Disease, Cytomegalovirus Infections, Heart Transplant Infection, Antiviral Toxicity, Neutropenia | 10/25 | 12/25 | | |
NCT05626530: Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients |
|
|
| Recruiting | 4 | 25 | US | Letermovir, Active drug | Tufts Medical Center | Cytomegalovirus Infections, Infection in Solid Organ Transplant Recipients, Neutropenia, Antiviral Toxicity | 12/25 | 12/25 | | |
2020-002924-35: Traitement prénatal de l'infection congénitale à cytomégalovirus par le letermovir randomisé contre le valaciclovir Traitement prénatal de l'infection congénitale à cytomégalovirus par le letermovir randomisé contre le valaciclovir |
|
|
| Not yet recruiting | 3 | 56 | Europe | Valaciclovir Arrow, Prevymis, Tablet, Valaciclovir Arrow 500 mg, Prevymis | ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS, ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS | Step 1: Maternal administration of 1 tablet of Letermovir (240 mg or 480 mg /day) during 3 days before TOPStep 2: Maternal daily administration of 240 or 480 milligrams of letermovir (1x240 mg-tablets) or (1x480 mg-tablets) (the dose will be choosen depending on the results obtained on step 1) up-until delivery or TOP Étape 1 : Administration maternelle d'un comprimé de Letermovir (240 mg ou 480 mg /jour) pendant 3 jours avant l’IMGÉtape 2 : Administration quotidienne par la mère de 240 ou 480 milligrammes de létermovir (1x240 mg) ou (1x480 mg) (la dose sera choisie en fonction des résultats obtenus à l'étape 1) jusqu'à l'accouchement ou IMG, Pregnant women with a fetus infected with cytomegaloviru.Test the efficacy of a new antiviral Letermovir on cytomegalovirus infection in the fetus versus the Valaciclovir already used in this context. Femmesenceintesavec fœtus infecté par le cytomégaloviruTester l’efficacitéd’unnouvel antiviralleLetermovirsurl’infection cytomégalovirus du fœtus versus le Valaciclovir déjà utilisé dans ce contexte., Diseases [C] - Virus Diseases [C02] | | | | |
NCT06341686: Evaluation of the Prophylactic Use of Letermovir in Kidney Transplant Recipients at Risk of Cytomegalovirus Infection |
|
|
| Not yet recruiting | 3 | 100 | NA | Letermovir 480 MG, Ganciclovir | Hospital do Rim e Hipertensão | CMV Infection | 03/25 | 05/25 | | |
MK-8228-045, NCT05763823: A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of CMV Infection in Chinese Hematopoietic Stem Cell Transplant Recipients |
|
|
| Completed | 3 | 120 | RoW | Letermovir, MK-8228 | Merck Sharp & Dohme LLC | Cytomegalovirus Infection | 04/24 | 04/24 | | |
NCT06407232: Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients |
|
|
| Recruiting | 3 | 90 | US | Letermovir, Prevymis | University of Wisconsin, Madison, Merck Sharp & Dohme LLC | Cytomegalovirus Infections, Kidney Transplant Infection, Pancreas Transplant | 09/26 | 09/26 | | |
| Recruiting | 3 | 80 | Europe | Letermovir, Valganciclovir, Letermovir placebo | Assistance Publique - Hôpitaux de Paris | Cytomegalovirus Infection | 09/27 | 11/27 | | |
NCT05711667: A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients |
|
|
| Active, not recruiting | 3 | 143 | US | Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Letermovir, 2-((4S)-8-Fluoro-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3-(2-methoxy-5-(trifluoromethyl)phenyl)-4H-quinazolin-4-yl)acetic Acid, AIC246, MK-8228, Prevymis | Children's Oncology Group | Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | 06/28 | 06/28 | | |
| Recruiting | 3 | 46 | NA | Letermovir, Valacyclovir | Assistance Publique - Hôpitaux de Paris | Pregnant Women, CMV Infected Fetuses | 08/29 | 08/29 | | |
2022-001514-18: Cytomegalovirus Prophylaxis with Letermovir in Heart Transplant Recipients: A Non-randomized Cohort Pilot Study |
|
|
| Not yet recruiting | 2 | 90 | Europe | Prevymis, Film-coated tablet, Prevymis | University Medical Center Ljubljana, MSD | The focus of investigation in the proposed study protocol is the rates of Cytomegalovirus viremia and/or disease in patients after heart transplantation undergoing novel CMV prophylaxis protocol using letermovir., CMV infection is the most prevalent infection after heart transplantation (HTX), occurring in up to 40-60% of the recipients. It most frequently occurs within the first 6 months after transplantation. | | | | |
| Completed | 2 | 65 | Europe, Japan, US, RoW | Letermovir oral granules, MK-8228, AIC246, AIC001, Letermovir tablet, Letermovir intravenous | Merck Sharp & Dohme LLC | Cytomegalovirus (CMV) Infection | 01/23 | 08/23 | | |
NCT04312841: Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab |
|
|
| Active, not recruiting | 2 | 6 | US | Letermovir, 2-((4S)-8-Fluoro-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3-(2-methoxy-5-(trifluoromethyl)phenyl)-4H-quinazolin-4-yl)acetic Acid, AIC246, MK-8228, Prevymis | Ohio State University Comprehensive Cancer Center, Merck Sharp & Dohme LLC | B-Cell Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia, Peripheral T-Cell Lymphoma, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome, T-Cell Prolymphocytic Leukemia | 04/24 | 12/24 | | |
NCT06453460: Prospect Eval of Efficacy of CMV-TCIP Direct Letermovir Prophylax After Allogen Hemato Cell Transpla |
|
|
| Recruiting | 2 | 50 | US | Letermovir, CMV T Cell Immunity Panel (CMV-TCIP), CMV DNA PCR | University of California, Irvine, Eurofins Viracor | CMV, Allogeneic Stem Cell Transplantation | 06/28 | 06/29 | | |
NCT04017962: A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection |
|
|
| Active, not recruiting | 2 | 102 | US | Letermovir Pill, LTV, blood draw | Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme LLC | CMV, CMV Infection, Hematopoietic Cell Transplant | 07/25 | 07/25 | | |
NCT05041426: Letermovir for CMV Prevention After Lung Transplantation |
|
|
| Active, not recruiting | 2 | 16 | US | Letermovir, Prevymis, Valganciclovir | Fernanda P Silveira, MD, MS, Merck Sharp & Dohme LLC | Lung Transplant, CMV | 07/25 | 07/25 | | |
NCT06021210: Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS |
|
|
| Recruiting | 2 | 80 | RoW | Letermovir Pill, Letermovir Tablets | The First Affiliated Hospital of Soochow University | CMV Infection, Hematopoietic Stem Cell Transplantation | 07/24 | 09/25 | | |
PROACTIV, NCT06626555: Clinical Trial to Evaluate the Effects of Letermovir Prophylaxis on T-cell Immune Activation in Participants With Treated HIV-1 Infection |
|
|
| Not yet recruiting | 2 | 36 | NA | Letermovir | University College, London, Royal Free Hospital NHS Foundation Trust | HIV | 03/26 | 03/26 | | |
ELICIT, NCT04840199: A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes. |
|
|
| Completed | 2 | 44 | US | Letermovir 240 MG Oral Tablet, PREVYMIS, Letermovir 480 MG Oral Tablet, Combination ART | National Institute of Allergy and Infectious Diseases (NIAID), Merck Sharp & Dohme LLC | HIV Infections, Cytomegalovirus, CMV | 11/23 | 11/23 | | |
NCT04060277: Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation |
|
|
| Active, not recruiting | 2 | 7 | US | Letermovir, 2-((4S)-8-Fluoro-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3-(2-methoxy-5-(trifluoromethyl)phenyl)-4H-quinazolin-4-yl)acetic Acid, AIC246, MK-8228, Prevymis, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, CMV-MVA Triplex Vaccine, Multi-antigen CMV-Modified Vaccinia Ankara Vaccine, Placebo Administration | City of Hope Medical Center, National Cancer Institute (NCI) | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Hodgkin Lymphoma, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma | 06/23 | 04/30 | | |
NCT05969743: Letermovir Prophylaxis for Cytomegalovirus (CMV) in Patients With Graft-versus-host Disease |
|
|
| Not yet recruiting | 2 | 42 | NA | Letermovir | Rabin Medical Center | Graft-versus-host-disease, CMV | 04/25 | 07/25 | | |
| Recruiting | 2 | 90 | Europe | Letermovir Pill | University Medical Centre Ljubljana | CMV Viremia | 08/25 | 08/26 | | |
NCT06066957: Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients |
|
|
| Recruiting | 2 | 80 | US | Letermovir 480 MG [Prevymis] | University of Pennsylvania, Merck Sharp & Dohme LLC | Cytomegalovirus Infections, Transplant-Related Disorder | 08/26 | 08/26 | | |
LETERCOR, NCT06057194: Efficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir. |
|
|
| Not yet recruiting | 2 | 90 | Europe | Letermovir 240 mg Oral Tablet | Maimónides Biomedical Research Institute of Córdoba, MERCK SHARP & DOHME DE ESPAÑA S.A. | Infections, Cytomegalovirus | 04/27 | 04/27 | | |
NCT06118515: A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus |
|
|
| Recruiting | 1 | 12 | US | Letermovir | National Institute of Allergy and Infectious Diseases (NIAID) | Congenital Cytomegalovirus Infection | 08/25 | 08/25 | | |
NCT06306989: Observational Clinical Study of Letermovir for Preventing CMV Infection After Allo-HSCT |
|
|
| Recruiting | N/A | 150 | RoW | Letermovir | Cao Weijie | Letemovir for the Prevention of CMV Infection After Allo-HSCT | 09/24 | 12/25 | | |
| Recruiting | N/A | 140 | Europe | Determination of HCMV DNA in plasma after DNAse digestion., Determination of HCMV DNA in blood or plasma. | Fondazione IRCCS Policlinico San Matteo di Pavia, Ministero della Salute, Italy | Cytomegalovirus Infections, Cytomegalovirus Viremia, Hematopoietic Stem Cell Transplantation | 06/25 | 03/26 | | |
NCT06211543: Letermovir (LMV) Prophylaxis in CMV-seronegative Allogeneic Stem Cell Transplant Recipients With CMV Seropositive Donors: an Exploratory Study From Spanish GETH/TC Centers |
|
|
| Not yet recruiting | N/A | 80 | NA | | Grupo Espanol de trasplantes hematopoyeticos y terapia celular | CMV | 09/25 | 03/26 | | |
NCT06441669: Effect of Letermovir Prophylaxis on CMV-specific Immune Reconstitution Post UCBT |
|
|
| Recruiting | N/A | 60 | RoW | Letermovir | Anhui Provincial Hospital | Cytomegalovirus Infection Reactivation | 05/26 | 05/26 | | |
NCT06449586: CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT |
|
|
| Recruiting | N/A | 250 | RoW | Letermovir | Ruijin Hospital | Hematologic Malignancy | 06/25 | 06/26 | | |
NCT06524973: Telehealth Self-Management Coaching Sessions to Improve Quality of Life in Pancreatic Cancer Survivors and Their Family Care Givers |
|
|
| Recruiting | N/A | 136 | US | Telemedicine, Counseling, Best Practice, Questionnaire Administration, Inrweview | City of Hope Medical Center | Metastatic Pancreatic Adenocarcinoma | 05/27 | 05/27 | | |
NCT06639854: The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients |
|
|
| Recruiting | N/A | 105 | US | Hematopoietic Cell Transplant | M.D. Anderson Cancer Center | Cytomegalovirus Cell Mediated Immunity, Hematopoietic Cell Transplant | 12/26 | 12/26 | | |
NCT05656599: Immune Reconstitution to CMV After HSCT: Impact of Clinical Factors and Therapy Strategies |
|
|
| Enrolling by invitation | N/A | 120 | RoW | Letermovir | Peking University People's Hospital | CMV Infection, Hematopoietic Stem Cell Transplantation | 12/24 | 12/25 | | |
NCT05789615: Letermovir Prophylaxis for CMV Infection in Haplo-HSCT Recipients: Single-center Data in China |
|
|
| Recruiting | N/A | 200 | RoW | Letermovir | The First Affiliated Hospital of Soochow University | CMV Infection, Hematopoietic Stem Cell Transplantation | 12/24 | 12/24 | | |
NCT06575374: Single Arm Pilot Trial of Letermovir for CMV Prophy in CAR T Cell |
|
|
| Recruiting | N/A | 36 | US | Letermovir | M.D. Anderson Cancer Center | Cell Therapy | 08/26 | 08/27 | | |
| Recruiting | N/A | 60 | Canada | Letermovir, PREVYMIS | Jean-Pierre Routy | People Living With HIV | 04/25 | 12/25 | | |
